Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.0M | $356M | $520M | $561M | $687M | $774M | $1.14B | $1.39B | $2.03B | $3.18B |
| Revenue growth | — | 709.0% | 45.9% | 7.8% | 22.6% | 12.6% | 47.8% | 21.2% | 46.7% | 56.4% |
| Operating income | $11.7M | $35.1M | $88.4M | $32.4M | $80.5M | $98.2M | $104M | $84.6M | $89.3M | $78.5M |
| Operating margin | 26.5% | 9.9% | 17.0% | 5.8% | 11.7% | 12.7% | 9.1% | 6.1% | 4.4% | 2.5% |
| Net income | $11.5M | $25.8M | $10.8M | $14.1M | $37.9M | $68.9M | $45.2M | $60.7M | $43.1M | $22.5M |
| Net margin | 26.0% | 7.2% | 2.1% | 2.5% | 5.5% | 8.9% | 3.9% | 4.4% | 2.1% | 0.7% |
| EPS (diluted) | $0.41 | $0.90 | $0.29 | $0.39 | $1.01 | $1.52 | $0.99 | $1.29 | $0.90 | $0.46 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $21.9M | $51.8M | $25.5M | $13.7M | $46.2M | $70.3M | $82.1M | $68.2M | $52.2M | $115M |
| Capital expenditures | $3.31M | $2.08M | $1.17M | $1.04M | $1.16M | $19.2M | $22.9M | $28.5M | $8.03M | $10.1M |
| Free cash flow | $18.6M | $49.7M | $24.3M | $12.6M | $45.0M | $51.1M | $59.2M | $39.7M | $44.2M | $104M |
| Share buybacks | $518K | $3.18M | $5.05M | $7.57M | $537K | $5.74M | $9.25M | $100M | $900K | $14.1M |
| Dividends paid | $26.7M | $10.4M | $17.8M | $61.7M | $51.3M | $31.1M | $14.0M | $62.1M | $4.04M | $7.88M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $54.8M | $99.7M | $107M | $103M | $193M | $233M | $288M | $294M | $288M | $429M |
| Total assets | $350M | $491M | $513M | $729M | $817M | $852M | $966M | $933M | $1.35B | $2.22B |
| Total liabilities | $99.6M | $154M | $106M | $368M | $372M | $336M | $408M | $523M | $841M | $1.66B |
| Long-term debt | — | — | $0.00 | $232M | $230M | $183M | $203M | $259M | $425M | $991M |
| Shareholders' equity | $87.2M | $160M | $181M | $192M | $331M | $455M | $543M | $614M | $713M | $779M |
| Retained earnings | -$773K | $1.73M | $17.8M | $31.9M | $69.8M | $144M | $182M | $243M | $286M | $308M |
| Shares (wtd avg diluted) | 28.0M | 28.7M | 37.9M | 36.4M | 37.4M | 45.4M | 45.6M | 46.9M | 48.0M | 49.4M |
Every figure is extracted from Astrana Health, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.